<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286906</url>
  </required_header>
  <id_info>
    <org_study_id>2019_11</org_study_id>
    <secondary_id>2019-A02795-52</secondary_id>
    <nct_id>NCT04286906</nct_id>
  </id_info>
  <brief_title>Multidimensional Assessment of Dyspnea in Asthma</brief_title>
  <acronym>MIDAS</acronym>
  <official_title>Multidimensional Assessment of Dyspnea in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breathlessness is a symptom of asthma that occurs in relation with lower airway obstruction.&#xD;
      However, this sensation is not specific of asthma and may be the expression of other&#xD;
      disorders. In particular, it can testify to anxiety or hyperventilation, two disorders&#xD;
      frequently associated with asthma. The systematic interpretation of dyspnea as a&#xD;
      manifestation of asthma in asthmatic patients may lead to an inappropriate increase in asthma&#xD;
      controllers.&#xD;
&#xD;
      Identifying the cause of dyspnea in asthmatic patients (airway obstruction, anxiety or&#xD;
      hyperventilation) is therefore crucial for the clinician.&#xD;
&#xD;
      This could be facilitated by a multidimensional assessment of dyspnea, evaluating the kind of&#xD;
      sensation felt by the patient (for example chest tightness, air hunger etc.) and emotions&#xD;
      associated to respiratory sensations (for example anxiety, fear etc.).&#xD;
&#xD;
      The objectives of this project are to assess: (1) the sensory and affective dimensions of&#xD;
      dyspnea in asthma and, (2) their connection to asthma control, anxiety and depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the sensory and affective dimensions of dyspnea</measure>
    <time_frame>At baseline</time_frame>
    <description>MultiDimensional Profile (MDP) scores QS and A2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between dyspnea intensity and asthma control</measure>
    <time_frame>At baseline</time_frame>
    <description>Correlation between MDP scores QS and A2 and ACQ-5 Correlation between MDP scores QS and A2 and ACQ-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between dyspnea intensity and anxiety</measure>
    <time_frame>At baseline</time_frame>
    <description>Correlation between MDP scores QS and A2 and anxiety score HAD-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between dyspnea intensity and hyperventilation</measure>
    <time_frame>At baseline</time_frame>
    <description>Correlation between MDP scores QS and A2 and the Nijmegen score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between change in dyspnea intensity and in asthma control</measure>
    <time_frame>Difference between baseline and 6 months</time_frame>
    <description>Correlation between change in MDP scores QS and A2 and change in ACQ-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between change in dyspnea intensity and in anxiety</measure>
    <time_frame>Difference between baseline and 6 months</time_frame>
    <description>Correlation between change in MDP scores QS and A2 and change in HAD-A score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between change in dyspnea intensity and in hyperventilation</measure>
    <time_frame>Difference between baseline and 6 months</time_frame>
    <description>Correlation between change in MDP scores QS and A2 and change in the Nijmegen score</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>One group (cohort)</arm_group_label>
    <description>Asthmatic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen</description>
    <arm_group_label>One group (cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asthmatic patients reporting breathlessness&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of asthma confirmed by:&#xD;
&#xD;
               -  A history of symptoms compatible with asthma&#xD;
&#xD;
               -  AND a history of airway obstruction, according to the GINA definition (2017):&#xD;
                  FEV1/FVC ratio lower than the lower limit of the predicted value at baseline or&#xD;
                  after a bronchial provocation test&#xD;
&#xD;
               -  AND a variability of airway obstruction defined by at least one of the following&#xD;
                  criteria:&#xD;
&#xD;
             oReversibility of airway obstruction after bronchodilators (400 µg of salbutamol): FEV&#xD;
             1 increases by&gt; 200 mL and&gt; 12% compared to baseline&#xD;
&#xD;
               -  OR delta peak-flow over the day / average peak-flow averaged over 2 weeks&gt; 10%&#xD;
&#xD;
               -  OR variability in FEV1 between two visits&gt; 200 mL and&gt; 12%&#xD;
&#xD;
               -  OR an increase in FEV1 of&gt; 200 mL and&gt; 12% compared to the baseline after 4 weeks&#xD;
                  of treatment with oral corticosteroids&#xD;
&#xD;
               -  OR a positive methacholine challenge: decrease in FEV1 by more than 20% for a&#xD;
                  dose &lt;1600 µg&#xD;
&#xD;
          2. Experience of dyspnea in the past 7 days&#xD;
&#xD;
          3. Age&gt; 18 years old&#xD;
&#xD;
          4. Social protection affiliation 5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years old&#xD;
&#xD;
          2. Active smoker or quitting smoking for less than a year&#xD;
&#xD;
          3. Severe exacerbation or respiratory infection within 4 weeks before inclusion (severe&#xD;
             exacerbation is defined by an increase in systemic corticosteroid therapy for at least&#xD;
             3 days or injection of a single dose of delayed corticosteroid, emergency room visit&#xD;
             due to asthma (with systemic corticosteroid therapy), or hospitalization due to&#xD;
             asthma).&#xD;
&#xD;
          4. Inability to respond to questionnaires for any reason&#xD;
&#xD;
          5. Presence of any pathology other than asthma which may be responsible for dyspnea, in&#xD;
             particular cardiovascular or respiratory (ischemic heart disease, heart failure,&#xD;
             chronic obstructive pulmonary disease, diffuse interstitial pneumonitis, lung cancer,&#xD;
             non-exhaustive list) with the exception of anxiety and hyperventilation syndrome&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Persons under guardianship&#xD;
&#xD;
          8. Refusal to sign consent or participate in the study&#xD;
&#xD;
          9. No social protection affiliation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Cécile Chenivesse, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cécile Chenivesse, MD PhD</last_name>
    <phone>3 20 44 59 48</phone>
    <phone_ext>+33</phone_ext>
    <email>cecile.chenivesse@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ch Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Vincent - Saint Antoine - Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hop Calmette Chu Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Chenivesse, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hu Paris Nord Site Bichat Aphp - Paris 18</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hu Paris Sud Site Kremlin Bicetre Aphp - Le Kremlin Bicetre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Breathlessness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

